Market research future has a Half Cooked Research Report on Global Adrenocortical Carcinoma Treatment market. The Report Explores Scope of the Study as Research Objective, Assumptions and Limitations in-depth. The report gives Market Dynamics by Major Drivers, Restraints, Opportunities and Challenges.
Adrenocortical Carcinoma Treatment Market – Highlights
Adrenocortical carcinoma (ACC) is a rare and highly aggressive carcinoma. According to the US National Library of Medicine, the overall 5-year mortality rate of 75 – 90% and an average survival from the time of diagnosis of 14.5 months. The rising incidence rate, a rise in the number of drugs in clinical trials for specific chemotherapeutics, and the increase in risk-factors are anticipated to drive the growth of the market during the assessment period. According to the International Pediatric Adrenocortical Tumor Registry, the female-to-male ratio for adrenocortical carcinoma is approximately 2.5-3:1. Inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increased incidences of adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of malignancies in BWS. However, differentiation of benign and malignant tumor in the initial stages needs proper evaluation. The pathohistological diagnosis also remains challenging. These factors coupled with the lack of oncology experts may restrain the growth of the market during the forecast period.
The global adrenocortical carcinoma treatment market has been segmented into type, therapy, and end-user.
Request Sample copy at https://www.marketresearchfuture.com/sample_request/6567
Regional Analysis:
On a regional basis, the adrenocortical carcinoma treatment market in the Americas is anticipated to dominate the market during the forecast period. The market growth in this region is owing to the advanced healthcare expenditure and advancements in medical device technologies. Moreover, higher demand for quality products and the availability of reimbursement policies are expected to contribute to the market growth in this region.
Competitive Players:
Some of the key players in the global adrenocortical carcinoma market are Pfizer Ltd., Arqule, EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. ,Ltd., Hitachi, Ltd., NeuroLogica Corp., and Digirad Corporation.
Some Points from TOC of Adrenocortical Carcinoma Treatment Market Research Report – Forecast to 2023:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
TOC CONTINUED….
Browse Complete 100 Pages Premium Research Report Enabled with 102 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/adrenocortical-carcinoma-treatment-market-6567
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Your information will never be shared with any third party.